Clinical trials: Oxaliplatin, open to volunteers
Advanced Solid Tumors
A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies
Phase 1 first-in-human, open-label, dose-escalation (3 + 3), dose-expansion clinical trial to evaluate the safety, tolerability and preliminary clinical efficacy of M3T01 (fully human IgG4/kappa monoclonal antibody targeting…
- Trial name
- NCT06719362
- Testing
- M3T01, Pembrolizumab, Chemoradiation
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Providence Health & Services
Rectal Cancer Patients
Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）
To evaluate the safety and preliminary efficacy of preoperative chemotherapy and PD-1 inhibitor Tislelizumab for Rectal Cancer patients.Go through laboratory and medical tests to verify eligibility to enter the study, receive the…
- Trial name
- NCT06647680
- Testing
- Receive the experimental combination of drugs (chemoradiation (Oxaliplatin and Capecitabine) + PD-1 inhibitor (Tislelizumab) for 3 cycles
- Where
- China
- Volunteers
- 35 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Colon Cancer (Stage II &Amp;Amp; III)
mFOLFOXIRI Plus PD-1 Inhibitor vs mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced Colon Cancer
In patients with high-risk stage II and stage III colon cancer, curative surgery followed by adjuvant chemotherapy with FOLFOX or CAPOX regimens has become the standard treatment.
- Trial name
- OPTICAL-3 (NCT06890624)
- Testing
- cmFOLFOXIRI plus PD-1 inhibitor, mFOLFOX6
- Volunteers
- 138 people
- Sponsor
- Sun Yat-sen University
Locally Advanced Rectal Cancer
Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer
This study is a single-arm, prospective, phase II clinical study to evaluate the efficacy and safety of preoperative short-course radiotherapy combined with ivonescimab and chemotherapy + total mesorectal excision(TME) surgery in…
- Trial name
- NCT06760520
- Testing
- Ivonescimab (SMT112 or AK112) Injection
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Relapsed/Refractory Large B-Cell Lymphoma
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
To evaluate the efficacy and safety of Linperlisib combined with standard immunochemotherapy in patients with R/R LBCL.
- Trial name
- NCT06489808
- Testing
- Linperlisib, Rituximab, Gemcitabine
- Where
- China
- Volunteers
- 89 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Intratumoral Injection, Cancer
The Clinical Efficacy and Safety of Intratumoral Injection of Chemotherapy for Advanced Solid Tumors
This project intends to investigate the clinical efficacy of intra-tumoural injection of chemotherapeutic agents (e.g. cisplatin, oxaliplatin, etc.)via fine needle aspiration guided by CT or ultrasound in patients with advanced…
- Trial name
- NCT06430515
- Testing
- Intratumoral Injection of Chemotherapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Wuxi People's Hospital
Intrahepatic Cholangiocarcinoma
HAIC Plus QL1706 & Bevacizumab in Unresectable HER2-Negative ICC
Intrahepatic cholangiocarcinoma (ICC) has an increasing global incidence, and over 70% of patients are diagnosed at unresectable stages with limited survival benefits from standard first-line chemotherapy regimens.
- Trial name
- NCT07841574
- Testing
- hepatic arterial infusion chemotherapy (HAIC) combine with QL1706 and bevacizumab
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Lianghe Lu
PDAC - Pancreatic Ductal Adenocarcinoma
PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment
The main objective of PANORAMIX phase II trial is to optimize first-lie (L1) NALIRIFOX treatment for pancreatic cancer through the implementation of 5-fluorouracil (5-FU) maintenance therapy.
- Trial name
- PANORAMIX (NCT07028424)
- Testing
- Nal-IRI, Ciprofloxacin, Paclitaxel
- Where
- 12 sites in France
- Volunteers
- 206 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Rectal Neoplasms Malignant, Radiotherapy
Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer
This phase II/III trial studies how well neoadjuvant short-course radiotherapy and chemotherapy with or without PD-1 inhibitors works in treating patients with locally advanced rectal adenocarcinoma.
- Trial name
- NCT05484024
- Testing
- Sintilimab, Short-course radiotherapy, CAPOX/mFOLFOX
- Where
- 2 sites in China
- Volunteers
- 588 people
- Sponsor
- Chinese Academy of Medical Sciences
HCC
Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.
Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC-positive patients have a higher rate of postoperative recurrence.
- Trial name
- NCT06311942
- Testing
- HAIC plus PD-1 inhibitors plus lenvatinib, PD-1 inhibitors plus lenvatinib
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Chen Xiaoping
Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC
The purpose of this study is to evaluate the pharmacokinetic (PK) profile, safety, and efficacy of tislelizumab administered once every 2 weeks (Q2W) or once every 4 weeks (Q4W) in combination with chemotherapy as first-line…
- Trial name
- NCT07733180
- Testing
- Tislelizumab, Oxaliplatin, Leucovorin
- Where
- 4 sites in Japan
- Volunteers
- 30 people
- Sponsor
- BeOne Medicines
Gastric Adenocarcinoma
Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer
This is a single-center, single-arm, phase 2 clinical study testing a new neoadjuvant (pre-surgery) treatment for patients with locally advanced gastric cancer or gastroesophageal junction (GEJ) cancer.
- Trial name
- NCT07867392
- Testing
- Iparomlimab and Tuvonralimab (QL1706), nab-P-SOX（nab-paclitaxel, oxaliplatin, S-1）
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Ruijin Hospital
Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma
Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer
This study aims to evaluate the effectiveness and safety of a preoperative treatment (called neoadjuvant therapy) combining four drugs-nab-paclitaxel, oxaliplatin, S-1, and sintilimab-for patients with locally advanced…
- Conditions
- Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma, Locally Advanced
- Trial name
- YOUNG-NEOS (NCT07018063)
- Testing
- nab-paclitaxel, oxaliplatin, S-1
- Where
- China
- Volunteers
- 35 people
- Sponsor
- zhoujing
Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer), Pancreatic Ductal Adenocarcinoma (PDAC)
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
The goal of this interventional clinical study is to learn the safety and preliminary efficacy of XH001 injection (Personalized mRNA tumor neoantigen vaccine) combined with standard adjuvant treatment in treating patients with…
- Conditions
- Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer), Pancreatic Ductal Adenocarcinoma (PDAC), Hepatocellular Carcinoma (HCC), Gastric Cancer (GC)
- Trial name
- NCT07594964
- Testing
- XH001 Injection, mFOLFIRINOX Treatment Regimen
- Where
- 2 sites in China
- Volunteers
- 48 people
- Sponsor
- Shenzhen Xinhe Biomedical
Peripheral Neuropathy, Colorectal Cancer
Prevention of Oxaliplatin-induced Nerve Damage in the Body's Extremities
The purpose of this study is to examine the effect of supplementary polyunsaturated fatty acids on nerve damage in the body's extremitites of patients treated with oxaliplatin containing chemotherapy after surgery for colorectal…
- Trial name
- OxaNeuro (NCT05404230)
- Testing
- Fish oil, Corn oil
- Where
- 4 sites in Denmark
- Volunteers
- 120 people
- Sponsor
- Vejle Hospital
Locally Advanced Colorectal Cancer
Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
This is a prospective, open-label, single-center, phase II umbrella trial designed to evaluate the efficacy and safety of neoadjuvant therapy for locally advanced colorectal cancer.
- Trial name
- NCT07503639
- Testing
- SHR-1701, SHR-8068, Short-course radiotherapy
- Volunteers
- 134 people
- Sponsor
- Fudan University
Colorectal Cancer Liver Metastasis
PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM
To explore Progression-Free-Survival(FPS) of PULSAR(personalized ultrafractionated stereotactic adaptive radiotherapy) combined with PD-1 Ab and Chemotherapy plus Bevacizumabfor CRLM
- Trial name
- NCT06788171
- Testing
- Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy, Bevacizumab, Capecitabine
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Fujian Cancer Hospital
Esophageal Adenocarcinoma, Esophageal Cancer
Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma
This research study is for people who have locally advanced esophageal adenocarcinoma and are expected to receive chemotherapy. The purpose of this study is to compare the effectiveness of Liquid Nitrogen Spray Cryotherapy (LNSC)…
- Trial name
- NCT07222657
- Testing
- Standard of care chemotherapy, LNSC
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Case Comprehensive Cancer Center
Diffuse Large B Cell Lymphoma (DLBCL)
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
The purpose of this phase 1b/2 study is to evaluate the safety, tolerability, and antitumor activity of HDM2005 in combination with standard of care in participants with diffuse large B-cell lymphoma.
- Trial name
- NCT07124936
- Testing
- HDM2005, Rituximab or Rituximab biosimilar, Gemcitabine
- Where
- 21 sites in China
- Volunteers
- 97 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Adebrelimab (SHR-1316), Bevacizumab
Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial
his is a single-arm, phase II clinical study evaluating the efficacy and safety of low-dose bevacizumab (7.5 mg/kg, Q3W) plus adebrelimab (1200 mg, Q3W) combined with transarterial chemoembolization (TACE) followed by hepatic…
- Conditions
- Adebrelimab (SHR-1316), Bevacizumab, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07543783
- Testing
- Transarterial Chemoembolization (TACE), Hepatic Arterial Infusion Chemotherapy (HAIC, FOLFOX), Adebrelimab
- Volunteers
- 38 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University